Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
366 active trials6 approved drugs33 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,281 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03110484 | Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | unknown | Phase 2 | 44 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05417230 | RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | unknown | Phase 2 | 29 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 14, 2022 |
| clinicaltrials |
| NCT03898895 | COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer(CORRECT) | unknown | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05357196 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 68 | SciClone PharmaceuticalsINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT03603834 | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma | unknown | Phase 2 | 25 | Khon Kaen UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04979663 | GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04961788 | Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03951597 | Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03620292 | Fluorescence Image Guided Surgery in Cholangiocarcinoma(COUGAR) | unknown | Phase 1 / Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 100 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | unknown | Phase 2 | 100 | Benaroya Research InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523402 | Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis | unknown | Phase 2 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT02162914 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma(REACHIN) | unknown | Phase 2 | 66 | Erasme University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04333927 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer(ACCORD) | unknown | Phase 2 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04300959 | Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT03873532 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | unknown | Phase 2 / Phase 3 | 298 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT04111380 | Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers | unknown | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT04077983 | Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 4, 2019 | clinicaltrials |
| NCT03042182 | Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma(cholangio) | unknown | Phase 1 / Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02108145 | Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 70 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04027764 | Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer | unknown | Phase 2 | 30 | Dai, GuanghaiOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT03185988 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | unknown | Phase 2 | 100 | Shen LinOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT04004234 | A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT02350686 | XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy | unknown | Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT01821248 | A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis | unknown | Phase 2 | 25 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | Feb 21, 2019 | clinicaltrials |
| NCT03772132 | Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | unknown | Phase 2 | 100 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT03768375 | Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | unknown | Phase 2 | 150 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03702491 | Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma | unknown | Phase 2 | 138 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT03633773 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 9 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02836847 | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | unknown | Phase 2 | 152 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT03311789 | Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 17, 2017 | clinicaltrials |
| NCT01798147 | Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | unknown | Phase 2 | 24 | Johannes Gutenberg University MainzOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03144856 | Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers | unknown | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01755013 | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm(OXY1A) | unknown | Phase 1 / Phase 2 | 69 | University of ZurichOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02178280 | Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00003296 | Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer | unknown | Phase 2 | 26 | Brown UniversityOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT01811277 | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jun 15, 2022source: clinicaltrials